Wong B C, Wong W M, Yee Y K, Hung W K, Yip A W, Szeto M L, Li K F, Lau P, Fung F M, Tong T S, Lai K C, Hu W H, Yuen M F, Hui C K, Lam S K
Department of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong.
Aliment Pharmacol Ther. 2001 Dec;15(12):1959-65. doi: 10.1046/j.1365-2036.2001.01118.x.
Rabeprazole is a new proton pump inhibitor with more potent acid suppressive and anti-Helicobacter effects.
To compare two different regimens of rabeprazole-based triple therapy vs. 7-day omeprazole-based triple therapy for the eradication of Helicobacter pylori infection.
Patients with proven H. pylori infection were randomized to receive: (i) 7-day rabeprazole, 10 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg, all twice daily; (ii) 3-day rabeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg, all twice daily; or (iii) 7-day omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg, all twice daily. Endoscopy (CLO test, histology) was performed before randomization and 6 weeks after drug treatment.
One hundred and seventy-three patients were randomized. H. pylori eradication rates (intention-to-treat, n=173/per protocol, n=167) were 88%/91% for 7-day rabeprazole-based therapy, 72%/72% for 3-day rabeprazole-based therapy and 82%/89% for 7-day omeprazole-based therapy, respectively. The per protocol eradication rate was significantly better in the 7-day rabeprazole-based therapy and 7-day omeprazole-based therapy groups when compared to the 3-day rabeprazole-based therapy group (P=0.01 and P=0.04, respectively). Compliance was excellent and all three regimens were well tolerated.
The efficacy of seven-day rabeprazole-based triple therapy is similar to 7-day omeprazole-based triple therapy for the eradication of H. pylori infection.
雷贝拉唑是一种新型质子泵抑制剂，具有更强的抑酸和抗幽门螺杆菌作用。
比较两种不同的以雷贝拉唑为基础的三联疗法与7天的以奥美拉唑为基础的三联疗法根除幽门螺杆菌感染的效果。
确诊为幽门螺杆菌感染的患者被随机分为：（i）7天疗程，雷贝拉唑10毫克、阿莫西林1000毫克和克拉霉素500毫克，均每日2次；（ii）3天疗程，雷贝拉唑20毫克、阿莫西林1000毫克和克拉霉素500毫克，均每日2次；或（iii）7天疗程，奥美拉唑20毫克、阿莫西林1000毫克和克拉霉素500毫克，均每日2次。在随机分组前及药物治疗6周后进行内镜检查（CLO试验、组织学检查）。
173例患者被随机分组。以7天雷贝拉唑为基础的疗法幽门螺杆菌根除率（意向性分析，n = 173/符合方案分析，n = 167）分别为88%/91%，以3天雷贝拉唑为基础的疗法为72%/72%，以7天奥美拉唑为基础的疗法为82%/89%。与以3天雷贝拉唑为基础的疗法组相比，以7天雷贝拉唑为基础的疗法组和以7天奥美拉唑为基础的疗法组的符合方案根除率显著更高（分别为P = 0.01和P = 0.04）。依从性良好，所有三种疗法耐受性均良好。
以7天雷贝拉唑为基础的三联疗法在根除幽门螺杆菌感染方面的疗效与以7天奥美拉唑为基础的三联疗法相似。
